Panzyga (Human Normal Immunoglobulin)

Human Normal Immunoglobulin, the active ingredient in Panzyga, is an immunoglobulin presented as a sterile solution for intravenous use. It replaces deficient IgG antibodies in patients with primary or secondary immunodeficiency disorders, providing passive immunity through pooled human plasma‑derived IgG administered under medical supervision.

GNH USA supplies Panzyga as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global clinical demand, ensuring consistent product integrity and patient safety.

Panzyga is used in immunoglobulin replacement therapy to address antibody deficiencies across several disease categories.

Primary immunodeficiency diseases: restores IgG levels to reduce frequency and severity of infections. Secondary immunodeficiency after hematopoietic stem cell transplantation: provides passive immunity to prevent opportunistic infections. Hypogammaglobulinemia associated with chronic lymphocytic leukemia: supports immune function and lowers infection risk.

Panzyga may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache - Fever - Chills - Fatigue

Serious or Rare Side Effects: - Anaphylaxis - Thromboembolic events - Acute renal failure - Aseptic meningitis

When using Panzyga, careful assessment and monitoring are required to minimize risks. - Screen for IgA deficiency: patients with severe IgA deficiency may experience anaphylaxis. - Monitor renal function: risk of acute kidney injury, especially with high infusion rates. - Assess thrombotic risk: ensure adequate hydration and consider patient history of clotting disorders. - Avoid use in uncontrolled hyperviscosity syndromes: may exacerbate viscosity. - Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Panzyga can interact with other medicines, requiring attention to avoid or monitor co‑administration.

Major Interactions (Avoid): - Live attenuated vaccines: may be less effective and increase infection risk. - Concurrent administration of other IVIG products: may cause excessive plasma viscosity. - High-dose aspirin or NSAIDs: increase risk of renal toxicity during infusion.

Moderate Interactions (Monitor Closely): - Corticosteroids: may mask infusion reactions, monitor patient response. - Diuretics: may potentiate renal effects, check kidney function. - ACE inhibitors or ARBs: monitor blood pressure and renal parameters.